Tachyons Lifescience Profile
Key Indicators
- Authorised Capital ₹ 10.25 Cr
as on 16-11-2024
- Paid Up Capital ₹ 9.50 Cr
as on 16-11-2024
- Company Age 3 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 40.00 Cr
as on 16-11-2024
- Revenue %
(FY 2023)
- Profit 1518.38%
(FY 2023)
- Ebitda -307.56%
(FY 2023)
- Net Worth 201.07%
(FY 2023)
- Total Assets 392.84%
(FY 2023)
About Tachyons Lifescience
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.25 Cr and a paid-up capital of Rs 9.50 Cr.
The company currently has active open charges totaling ₹40.00 Cr.
Hareshkumar Shah, Anilkumar Gandhi, Santoshkumar Shah, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24299GJ2021PTC120075
- Company No.
120075
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Feb 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Sabarkantha, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media
Who are the key members and board of directors at Tachyons Lifescience?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hareshkumar Shah  | Director | 16-Nov-2021 | Current |
| Anilkumar Gandhi | Director | 16-Nov-2021 | Current |
| Santoshkumar Shah | Director | 08-Feb-2021 | Current |
| Bhupendra Shah | Director | 16-Nov-2021 | Current |
| Manharlal Mehta | Director | 16-Nov-2021 | Current |
Financial Performance of Tachyons Lifescience.
Tachyons Lifescience Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 1518.38% increase in profit. The company's net worth Soared by an impressive increase of 201.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tachyons Lifescience?
In 2023, Tachyons Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Tirupati Ores & Minerals Exim Private LimitedActive 13 years 8 months
Manharlal Mehta is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 01 Aug 2023 | ₹20.00 Cr | Open |
Sidbi Creation Date: 31 May 2023 | ₹19.00 Cr | Open |
Sidbi Creation Date: 18 May 2023 | ₹1.00 Cr | Open |
How Many Employees Work at Tachyons Lifescience?
Tachyons Lifescience has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tachyons Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tachyons Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
